Cargando…
On the Other Side: Manipulating the Immune Checkpoint Landscape of Dendritic Cells to Enhance Cancer Immunotherapy
Monoclonal antibodies targeting co-inhibitory immune checkpoint molecules have been successful in clinical trials of both solid and hematological malignancies as acknowledged by the 2018 Nobel Prize in Medicine, however improving clinical response rates is now key to expanding their efficacy in area...
Autores principales: | Kong, Benjamin Y., Bolton, Holly, Kim, Julius W., Silveira, Pablo A., Fromm, Phillip D., Clark, Georgina J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6372550/ https://www.ncbi.nlm.nih.gov/pubmed/30788290 http://dx.doi.org/10.3389/fonc.2019.00050 |
Ejemplares similares
-
Research Progresses in Immunological Checkpoint Inhibitors for Breast Cancer Immunotherapy
por: Zhang, Wenxiang, et al.
Publicado: (2021) -
The Landscape of Immunotherapy Resistance in NSCLC
por: Frisone, Daniele, et al.
Publicado: (2022) -
Metastasis: Other Side of the Coin
por: Ahmad, Aftab, et al.
Publicado: (2015) -
Editorial: The Biological Landscape of Immunotherapy in AML
por: Isidori, Alessandro, et al.
Publicado: (2021) -
Exploring the landscape of immunotherapy approaches in sarcomas
por: Pilavaki, Pampina, et al.
Publicado: (2023)